Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has earned an average recommendation of “Hold” from the six analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $5.84.

A number of research analysts recently issued reports on ZNTL shares. HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a report on Friday. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, August 9th. Finally, Wells Fargo & Company lowered their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, August 7th.

Zentalis Pharmaceuticals Stock Up 4.3%

Zentalis Pharmaceuticals stock opened at $1.71 on Monday. Zentalis Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $4.44. The firm’s fifty day moving average is $1.62 and its 200 day moving average is $1.44. The company has a market capitalization of $123.36 million, a PE ratio of -0.76 and a beta of 1.77.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Wednesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.19. Sell-side analysts expect that Zentalis Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Cerity Partners LLC raised its holdings in Zentalis Pharmaceuticals by 58.7% during the first quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock worth $33,000 after buying an additional 7,579 shares during the last quarter. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at about $31,000. Alpine Global Management LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the first quarter valued at about $48,000. SG Americas Securities LLC raised its holdings in shares of Zentalis Pharmaceuticals by 35.3% in the third quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock valued at $48,000 after purchasing an additional 8,236 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at about $37,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.